AI-based, digital pathology startup Proscia Inc. has partnered with the University of California at San Francisco (UCSF) to advance the practice of pathology via artificial intelligence (AI). The pair will start with prostate cancer and then plan to move on to validate approaches in several additional pathology subspecialties.
In an effort to gain new insights about the novel coronavirus sweeping the globe, Boston-based Biofourmis Inc. is leveraging its artificial intelligence (AI)-driven remote monitoring platform to monitor Hong Kong patients diagnosed or suspected of having COVID-19. The remote monitoring and disease surveillance program, which kicked off just a few days ago, is being administered by the University of Hong Kong and includes Biofourmis’ Hong Kong-based joint venture, Harmony Medical Inc.
An artificial intelligence (AI) platform developed by Naperville, Ill.-based Physiq Inc. gave researchers a mean of 10.4 days warning of an impending heart failure exacerbation that would require hospitalization or an emergency department visit, according to a study published in Circulation – Heart Failure.
PERTH, Australia – Australian medication adherence technology firm Adherium Ltd. is relaunching itself after a management reshuffle and a successful capital raise of AU$5.4 million (US$3.5 million) to deploy a new commercial strategy.
San Diego-based Cortechs Labs Inc. has developed an automated PET image analysis tool that identifies changes in specific brain structures associated with Alzheimer’s disease, vascular dementia, epilepsy, multiple sclerosis and other neurological disorders.
Artificial intelligence still has a lot to prove when it comes to its relevance in improving health care. But one bright spot was a deal last July between Dublin-based Medtronic plc and San Francisco-based startup Viz.ai Inc. to use the latter’s AI system that’s designed to spot a large vessel occlusion automatically in CT angiogram images.
The second day of the FDA workshop on artificial intelligence (AI) in health care featured several interesting proposals, including that AI will be used in health care without the aid of a health care professional. John Martin, chief medical officer at Butterfly Network Inc., of Guildford, Conn., said the time is ripe for AI-assisted ultrasound in the home, which he claimed could reduce rehospitalizations in heart failure, one of the holy grails in U.S. government efforts to restrain health care spending growth.
Developers of artificial intelligence (AI) algorithms have their own nightmares to deal with, but the FDA is charged with employing a regulatory touch that steers clear of rocky shoals on one side and inescapable whirlpools on the other. The FDA’s Bakul Patel said during a Feb. 25 workshop that the FDA would quickly be swamped if the agency took a traditional regulatory approach to managing the super-iterative digital health space, but that the agency will keep a keen eye on the potential impact on patients as AI begins to move into clinical practice.
U.S.-based device makers have been grappling with FDA cybersecurity requirements for some time, but now the European Union (EU) is working on cybersecurity regulations as well. Throw in privacy requirements by the state of California and the EU’s General Data Protection Regulation (GDPR), and device makers are facing an increasingly complicated world of enforcement and litigation.
Redwood City, Calif.-based Q Bio Inc., which is offering a quantitative assessment of personal health, has come out of stealth mode, scooping up $40 million in a series B funding round led by Andreessen Horowitz. The funds are earmarked to improve its proprietary platform and technology to make its preventive health services faster, better and more affordable for all.
RSS
